|
GLT8D1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.78550532534427E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.93350010949212E-10 |
| Normal-vs-Stage2 |
1.519690E-02 |
| Normal-vs-Stage3 |
8.34989855036383E-11 |
| Normal-vs-Stage4 |
2.22266649529956E-13 |
| Stage1-vs-Stage2 |
8.235500E-02 |
| Stage1-vs-Stage3 |
2.608800E-01 |
| Stage1-vs-Stage4 |
2.244400E-03 |
| Stage2-vs-Stage3 |
2.644400E-02 |
| Stage2-vs-Stage4 |
1.583580E-03 |
| Stage3-vs-Stage4 |
9.387500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.32389654794451E-11 |
| Normal-vs-AfricanAmerican |
1.848470E-04 |
| Normal-vs-Asian |
4.66380045693882E-10 |
| Caucasian-vs-AfricanAmerican |
6.104000E-01 |
| Caucasian-vs-Asian |
9.402000E-01 |
| AfricanAmerican-vs-Asian |
6.062400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.76180000272575E-08 |
| Normal-vs-Female |
2.66590083342066E-11 |
| Male-vs-Female |
6.081000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.41562325697942E-12 |
| Normal-vs-Age(41-60Yrs) |
4.58269999725758E-08 |
| Normal-vs-Age(61-80Yrs) |
8.75579997394738E-09 |
| Normal-vs-Age(81-100Yrs) |
1.621640E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.281210E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.165400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.429600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.312200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.652000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.050800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.754820E-04 |
| Classical-VS-Follicular |
1.357820E-02 |
| Classical-VS-Other |
9.066600E-01 |
| Classical-VS-Normal |
8.31024138392422E-12 |
| Tall-VS-Follicular |
1.83939999998106E-06 |
| Tall-VS-Other |
2.315200E-01 |
| Tall-VS-Normal |
1.64757096854373E-12 |
| Follicular-VS-Other |
4.902200E-01 |
| Follicular-VS-Normal |
9.585200E-04 |
| Other-VS-Normal |
1.009670E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.15039999976285E-07 |
| Normal-vs-N1 |
3.88578058618805E-15 |
| N0-vs-N1 |
2.42019999996401E-06 |
|
|
